1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow CD20-Positive Neoplastic Cells Present: new trials by email Literature Review of CD20-Positive Neoplastic Cells Present trials Research Report on CD20-Positive Neoplastic Cells Present
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma Dexamethasone, Ibrutinib, Lenalidomide - CCND1 Positive, CD20-Positive Neoplastic Cells Present | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-07-01 | 2019-08-22 |
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
CT-P10 (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Lenalidomide (1) · Rituximab (1) · auricularum (1) · dexamethasone 21-phosphate (1) · dexamethasone acetate (1) · ibrutinib (1)
M.D. Anderson Cancer Center (1)
P30CA016672 (1)